1612 (1612) Fair Value & Analysis

Healthcare · Market cap HK$488M

1 1612 1612 · HK

PriceHK$0.7400

Fair ValueHK$2.98

Upside+302.7%

Quality60/100

Watch 1612 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.68 – HK$4.29

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −10.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.4360 – HK$1.13 · fair‑value band HK$1.68 – HK$4.29 · the HK$0.7400 price screens below the HK$2.98 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1612 (1612) currently trades at HK$0.7400, while our model-based Fair Value estimate is HK$2.98 — implying the stock looks roughly 302.7% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, 1612 generated revenue of HK$933M at a net margin of 11.2%. Revenue grew 15.0% year over year. It earns a return on equity of 17.3%. The balance sheet holds a net cash position of HK$73.5M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$933M

Revenue growth (YoY) +15.0%

Net margin 11.2%

Return on equity 17.3%

Free cash flow HK$54.6M FY2025

P/E ratio 4.6

More key figures

Operating margin 13.5%

EPS (TTM) HK$0.0800

Dividend yield 6.8%

EPS growth (YoY) +46.2%

Net cash HK$73.5M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1612 reported revenue of HK$933M in FY2025 versus HK$778M in FY2021, a compound +4.7%/yr. Reported net income was HK$104M in FY2025, compounding +14.5%/yr from FY2021.

Revenue +4.7%/yr

FY21 HK$778M

FY22 HK$629M

FY23 HK$718M

FY24 HK$801M

FY25 HK$933M

Net income +14.5%/yr

FY21 HK$60.7M

FY22 −HK$17.4M

FY23 HK$57.3M

FY24 HK$69.2M

FY25 HK$104M

Is 1612 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,228 MXN	-23%
Abbott Laboratories, ABTT34	R$38.22	R$30.39	-20%
Stryker Corporation S1YK34	R$77.83	R$8.47	-89%
Medtronic plc MDT	$80.25	$74.40	-7%
Boston Scientific Corporation B1SX34	R$248.75	R$221.81	-11%
Edwards Lifesciences Corporation EW	$85.88	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1612 (1612) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$2.98 versus a price of HK$0.7400 — about +303% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1612?

Our model-based fair value for 1612 is HK$2.98 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.7400.

What is the quality score of 1612?

1612 has a Quality Score of 60/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1612 (1612)?

1612 reported trailing-twelve-month revenue of about HK$933M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1612?

The net profit margin of 1612 is about 11.2%, meaning it keeps roughly 11.2% of revenue as net income. Based on the latest reported figures.

Does 1612 pay a dividend?

1612 currently shows a dividend yield of about 6.76% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.